Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Lelais, G., Epple, R., Marsilje, T.H., Long, Y.O., McNeill, M., Chen, B., Lu, W., Anumolu, J., Badiger, S., Bursulaya, B., DiDonato, M., Fong, R., Juarez, J., Li, J., Manuia, M., Mason, D.E., Gordon, P., Groessl, T., Johnson, K., Jia, Y., Kasibhatla, S., Li, C., Isbell, J., Spraggon, G., Bender, S., Michellys, P.Y.(2016) J Med Chem 59: 6671-6689
- PubMed: 27433829 
- DOI: 10.1021/acs.jmedchem.5b01985
- Primary Citation of Related Structures:  
5FEQ, 5FEE, 5FED - PubMed Abstract: 
Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue a ...